



BEST AVAILABLE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov


APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/524,134	02/11/2005	Scott Koenig	11183-003-999	1503
20583	7590	04/10/2006	EXAMINER	
JONES DAY 222 EAST 41ST ST NEW YORK, NY 10017			CROWDER, CHUN	
			ART UNIT	PAPER NUMBER
			1644	

DATE MAILED: 04/10/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Amendment Due 7/10/06

(SL)





Office Action Summary

Application No.

10/524,134

Applicant(s)

KOENIG ET AL.

Examiner

Chun Crowder

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 30 January 2006.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-109 is/are pending in the application.
- 4a) Of the above claim(s) 2-8, 22, 24-29, 33-37, 39, 40, 44-80 and 91-103 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 9-21, 23, 30-32, 38, 41-43, 81-90, 104-109 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☒ Other: See Continuation Sheet.

Continuation of Attachment(s) 6). Other: Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures..

DETAILED ACTION

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

An amino acid sequence is disclosed on page 12 of the instant specification. However, the sequence fails to comply with the Sequence Rules.

Applicant is reminded of the Sequence Rules which require a submission for all sequences of 10 or more nucleotides or 4 or more amino acids (see 37 CFR 1.1821-1.1825) and is also requested to carefully review the submitted specification for any and all sequences which require compliance with the rules.

Applicant must comply with the requirements of the Sequence Rules (37 CFR 1.1821-1.1825) in response to this Office Action.

2. Applicant's election with traverse of Group II and species of antibody 2B6 without conjugation, filed 01/30/2006, is acknowledged.

The traverse is on the ground that Groups I and II have a special technical feature over the prior art teachings of Presta in that the instant inventions teaches the variable domains of the antibody are responsible for binding to the antigen while Presta teaches modified Fc region of an antibody that has altered binding to Fc receptors.

This is not found persuasive because the originally presented claims lack the same or corresponding special technical feature that is a contribution over the prior Presta for the reasons set forth in the Office Action mailed 11/30/2005.

In addition, the newly amended claims contain inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1 because under PCT Rule 13.2, they lack the same or corresponding special technical features over prior art of Weinrich et al. (Hybridoma. 1996, 15;2:109-116. Reference C68 in IDS) for the reasons stated in paragraph 11 of this Office Action.

Therefore, the restriction requirement is still deemed proper and is made FINAL.

Claims 1, 23, 39, 42, 81-90, and 105 have been amended.

Claims 108 and 109 have been added.

Claims 1-109 are pending.

Claims 2-8, 22, 24-29, 33-37, 39, 40, 44-80, 91-103 have been withdrawn from further consideration by the Examiner, under 37 C.F.R. 1.142(b), as being drawn to nonelected inventions.

Claims 1, 9-21, 23, 30-32, 38, 41-43, 81-90, 104-109, read on an isolated antibody of clone 2B6 without conjugation that binds to native FcγRIIB with greater affinity than FcγRIIA and antagonizes at least one activity of FcγRIIB, is currently under consideration.

3. Applicant's claim for domestic priority under 35 U.S.C. 119(e) and 35 U.S.C. 371 is acknowledged. The priority applications PCT/US03/25399 and 60/403,266 upon which benefit is claimed appear to provide adequate support under 35 U.S.C. 112 for subject matter claimed in the instant application.

The specification on page 1, line 1 should include a specific reference to the priority application PCT/US03/25399 for which benefit is sought and the status of the instant application is a 371.

4. Applicant's IDS, filed 07/15/2005, is acknowledged and considered.
5. The application is required to be reviewed and all spelling, TRADEMARK, and like error corrected.

Trademarks should be capitalized or accompanied by the TM or ® symbol wherever they appear and be accompanied by the generic terminology. Although the use of trademarks is permissible in patent application, the proprietary nature of the trademarks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

Appropriate correction is required.

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
7. Claims 9, 12, 31, 41, and 109 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A) Claim 9 and 14 are indefinite in the recitation of "at least one activity of FcγRIIB" and "B cell activity", respectively, because the metes and bounds of the activities is not clear and ambiguous. For example, pages 14 and 30 of the specification disclose certain "activities of FcγRIIB" and "B cell activities", respectively, however, it is unclear as to which "activities" or the requisite structural/functional characteristic is/are intended or encompassed by the claimed antibody.

It is suggested to amend the claims to recite the "activities of FcγRIIB " and/or "B cell activity" encompassed by the claimed antibody. See claim 13 for example.

B) Claim 31 is indefinite in the recitation of "immune response" because the metes and bounds of the "immune response" is not clear and ambiguous. For example, page 14 of the specification discloses certain "immune response"; however, it is unclear as to which "immune response" or the requisite structural/functional characteristic is/are intended or encompassed by the claimed antibody.

It is suggested to amend the claims to recite the "immune response " encompassed by the claimed antibody. See claim 32 for example.

C) Claim 41 are indefinite in the recitation of "'humanized". There is insufficient antecedent basis for this limitation in this claim. The clone 2B6 produces a monoclonal antibody, not a humanized antibody.

Applicant is suggested to amend the preamble of the claim to include "humanized antibody" and recite the source of the antibody accordingly.

D) Claim 109 is indefinite in the recitation of "denatured FcγRIIB" because the metes and bounds of "denature" is unclear and ambiguous. The phrase is not defined by the claims, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonable apprised of the metes and bounds of the invention.

E) Applicant is reminded that any amendment must point to a basis in the specification so as not to add new matter. See MPEP 714.02 and 2163.06.

Art Unit: 1644

8. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

9. Claims 38, 41-43 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

It is apparent that the **hybridoma 2B6 that produces the mouse monoclonal antibody** is required to practice the claimed invention. As a required element, it must be known and readily available to the public or obtainable by a repeatable method set forth in the specification. If it is not so obtainable or available, the enablement requirements of 35 USC 112, a deposit of the **hybridoma 2B6**, which produces this antibody, may satisfy first paragraph. See 37 CFR 1.801-1.809.

Applicant discloses on page 29 of the instant specification that hybridoma 2B6 producing the claimed antibody has been deposited with ATCC under Budapest Treaty on 08/13/2002. In addition to the conditions under the Budapest Treaty, applicant is required to satisfy that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent in US patent applications.

An affidavit or declaration by applicants or someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney of record over his or her signature, stating that the **hybridoma** has been deposited under the Budapest Treaty and that the **hybridoma will be irrevocably and without restriction or condition released to the public upon the issuance of a patent** would satisfy the deposit requirement made herein. See 37 CFR 1.808.

Further, the record must be clear that the deposit will be maintained in a public depository for a period of 30 years after the date of deposit or 5 years after the last request for a sample *or for the enforceable life of the patent whichever is longer*. See 37 CFR 1.806.

10. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

11. Claims 1, 9-16, 23, 30-32, 81-90, 108, and 109 are rejected under 35 U.S.C. 102(b) as being anticipated by Weinrich et al. (Hybridoma. 1996, 15;2:109-116. Reference C68 in IDS) (See entire document) as evidenced by Bolland et al. (Advances in Immunology. 1999. 72:149-177. Reference C04 in IDS) (See entire document) and Clynes et al. (Nature Medicine. 2000. 6;4:443-446. Reference C15 in IDS) (See entire document).

Weinrich et al. teach that a monoclonal antibody II8D2, made from mice immunized with recombinant FcγRIIB, is specific for FcγRIIB without cross-reactivity with FcγRIIA in phosphate buffered saline based ELISA (see entire document, particularly Material and Method on pages 110-111 and Results on pages 111-114). Weinrich et al. further teach that the anti-FcγRIIB antibody can be used to detect FcγRIIB on B cell line Daudi.

As evidenced by Bolland et al, crossing linking FcγRIIB antagonizes FcγRIIB activities such as B cell receptor-mediated signaling involving signaling molecules including Btk kinase, PLCγ, PI3 kinase, and SHIP (see entire document, particularly pages 154-156). Further, Bolland et al. teach that in addition to the inhibitory function on B cell activation, FcγRIIB can also inhibit FcR-triggered mast cell degranulation involving FcεRI (e.g. see page 157-158, in particular).

As further evidenced by Clynes et al, FcγRIIB is a potent regulator of antibody-dependent cell-mediate cytotoxicity (ADCC) and optimal antibody against tumors that binds less to FcγRIIB and more to FcγRIII would enhance ADCC (see entire document, particularly pages 444-445).

Given the properties of the prior art the FcγRIIB specific antibody; the claimed functional limitations would be inherent properties of the antibody. Also, the Courts have held that there is no requirement that those of ordinary skill in the art know of the inherent property. See MPEP 2131.01(d) and MPEP 2112-2113 for case law on inherency.

When claims recite using an old composition or structure (e.g. anti-FcγRIIB antibody) and the use is directed to a result or property of that composition or structure, then the claims are anticipated. See MPEP 2112.02. Also, see Mehl/Biophile International Corp. V. Milgraum, 52 USPQ2d 1303 (Fed. Cir. 1999); Atlas Powder Co. V. IRECO, 51 USPQ2d 1943 (Fed. Cir. 1999).

Therefore, the reference teachings anticipate the claimed invention.

12. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

13. Claims 1 and 17-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Reff et al. (Critical Review in Oncology/Hematology. 2001. 40:25-35) in view of Ott et al. (J. Allergy Clin. Immunol. 2001. 108:S95-S98) and Weinrich et al. (Hybridoma. 1996, 15;2:109-116. Reference C68 in IDS).

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Reff et al. teach that several approaches have been used to make antibody better tolerated in human, including (1) humanization approach where the original CDRs and a few key residues that impacted antigen binding were grafted from murine antibody onto a human antibody of similar structure; (2) human antibody approach using transgenic mice where the murine Ig genes have been replaced with human IgG genes (see entire document, particularly pages 26-28). Further, Reff et al. teach smaller versions of antibodies such as single chain antibody, antibody fragments including F(ab) and F(ab')₂ have been made to achieve better penetration of the avascular tumors (e.g. see pages 30-32, in particular).

Reff et al. do not teach humanized or human anti-FcγRIIB specific antibody, single chain antibody and its fragments.

However, targeting FcγRIIB for therapeutic advantages was well known in the art at the time the invention was made. For example, Ott et al. teach FcγRIIB mediated inhibitory signaling is important in regulating immune response because FcγRIIB-deficient mice exhibit enhanced antibody production and autoimmunity (see entire document, particularly pages S95-S96). Further, Ott et al. conclude that the development of therapeutics that specifically target FcγRIIB may be effective in the treatment of a variety of immunologic disorders (e.g. see Summary on page S97, in particular).

The teachings of Weinrich et al. have been discussed, supra, and teach method of making anti-FcγRIIB specific antibody.

Therefore, it would have been obvious to the ordinary artisan at the time the invention was made to make humanized or human anti-FcγRIIB specific antibody, its fragments, and single chain antibody. The ordinary artisan would have been motivated to do so for human therapies because the inhibitory FcγRIIB is a potential target for treating immunologic disorders and humanized or human antibodies are better tolerated in treating human patients; single chain antibodies and antibody fragments penetrate better in avascular tumors.

Given the teachings of Reff et al. regarding the advantages of humanized or human antibody, single chain antibody and antibody fragments, and the teachings of Ott et al. and Weinrich et al. regarding FcγRIIB being a potential therapeutic target and the method of making anti-FcγRIIB specific antibody, the ordinary artisan at the time the invention was made would have had a reasonable expectation of success of producing humanized or human anti-FcγRIIB specific antibody, single chain or antibody fragments that are specific for FcγRIIB.

Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

14. Claims 1 and 104-107 are rejected under 35 U.S.C. 103(a) as being unpatentable over Presta (US Patent 6,737,056) in view of Ott et al. (J. Allergy Clin. Immunol. 2001. 108:S95-S98) and Weinrich et al. (Hybridoma. 1996, 15;2:109-116. Reference C68 in IDS).

Presta teaches and claims antibodies with modified Fc region for higher affinity to FcγRIII and enhanced ADCC (see entire document, particularly columns 5-6 and claims 1-8).

Presta does not teach anti-FcγRIIB antibody.

The teachings of Ott et al. and Weinrich et al. have been discussed, *supra*.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the Fc region of the anti-FcγRIIB antibody for increased affinity for FcγRIII and enhanced ADCC because therapeutics that specifically target FcγRIIB may be effective in the treatment of a variety of immunologic disorders and higher affinity and enhanced ADCC can be achieved by modifying amino acids in the Fc region of antibodies.

Given the teachings of Presta regarding modifying Fc region of antibodies to achieve enhanced ADCC, and the teachings of Ott et al. and Weinrich et al. regarding FcγRIIB being a potential therapeutic target and the method of making anti-FcγRIIB specific antibody, the ordinary artisan at the time the invention was made would have had a reasonable expectation of success of producing Fc modified anti-FcγRIIB specific antibody with increased affinity for FcγRIII and enhanced ADCC.

Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

15. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

16. Claims 1, 9-21, 23, 30-32, 38, 41-43, 81-90, 104-109 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-13 and 16-20 of copending USSN. 11/305,787.

Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instant and the copending applications claims are drawn to same or nearly the same anti-FcγRIIB antibody that specifically binds the extracellular domain of human FcγRIIB and/or anti-FcγRIIB antibody with Fc modification.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

17. Claims 1, 9-21, 23, 30-32, 38, 41-43, 81-90, 104-109 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-6, 9, 10, 14, 15, 53-57, and 63 of copending USSN 11/108,135.

Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instant and the copending applications claims are drawn to same or nearly the same anti-FcγRIIB antibody with identical clone name 2B6 that specifically binds the extracellular domain of human FcγRIIB and/or anti-FcγRIIB antibody with Fc modifications.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

18. Claims 1, 9-21, 23, 30-32, 38, 41-43, 81-90, 104-109 directed to an invention not patentably distinct from claims 1-13 and 16-20 of commonly assigned USSN 11/305,787; and claims 1-6, 9, 10, 14, 15, 53-57, and 63 of commonly assigned USSN 11/108,135 for reasons stated above.

The U.S. Patent and Trademark Office normally will not institute an interference between applications or a patent and an application of common ownership (see MPEP Chapter 2300). Commonly assigned USSN 11/305,787 and USSN 11/108,135, discussed above, would form the basis for a rejection of the noted claims under 35 U.S.C. 103(a) if the commonly assigned case qualifies as prior art under 35 U.S.C. 102(e), (f) or (g) and the conflicting inventions were not commonly owned at the time the invention in this application was made. In order for the examiner to resolve this issue, the assignee can, under 35 U.S.C. 103(c) and 37 CFR 1.78(c), either show that the conflicting inventions were commonly owned at the time the invention in this application was made, or name the prior inventor of the conflicting subject matter.

A showing that the inventions were commonly owned at the time the invention in this application was made will preclude a rejection under 35 U.S.C. 103(a) based upon the commonly assigned case as a reference under 35 U.S.C. 102(f) or (g), or 35 U.S.C. 102(e) for applications pending on or after December 10, 2004.

19. No claim is allowed.

20. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chun Crowder whose telephone number is (571) 272-8142. The examiner can normally be reached Monday through Friday from 8:30 am to 5:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/524,134

Page 15

Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chun Crowder, Ph.D.

Patent Examiner

March 24, 2006

Philip Crowder
PHILIP CROWDER, PH.D.
PRINCIPAL EXAMINER
TC 600
3/27/06



Application No.: 10,524,134

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



Express Mail No. EV 654 849 984 US
Sheet 1 of 4

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	11183-003-999	10/524,134
	APPLICANT	
	Koenig et al.	
	FILING DATE	GROUP
	February 11, 2005	1644

U.S. PATENT DOCUMENTS

MATTER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C.C.	A01	4,179,337	12/18/1979	Davis et al.			
	A02	5,711,944	01/27/1998	Gilbert et al.			
	A03	5,888,533	03/30/1999	Dunn			
	A04	5,648,260	07/15/1999	Winter et al.			
	A05	5,945,115	08/31/1999	Dunn et al.			
	A06	6,019,968	02/01/2000	Platz et al.			
	A07	6,132,764	10/17/2000	Li et al.			
	A08	6,194,551	02/27/2001	Idusogie et al.			
	A09	6,218,149	04/17/2001	Morrison et al.			
	A10	2001/0036459	11/01/2001	Ravetch			
	A11	6,339,069	01/15/2002	Meers et al.			
	A12	2002/0028486	03/07/2002	Morrison et al.			
	A13	6,420,149	07/16/2002	Fukuda et al.			
	A14	6,472,511	10/29/2002	Leung et al.			
	A15	6,528,624	03/04/2003	Idusogie et al.			
	A16	2003/0115614	06/19/2003	Kanda et al.			
C.C.	A17	5,837,243	11/17/1997	Deo et al.			

FOREIGN PATENT DOCUMENTS

MATTER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
C.C.	B01	WO 94/18330 A1	08/18/1994	PCT			
	B02	WO 99/58572 A1	11/18/1999	PCT			
	B03	WO 00/42072 A1	07/20/2000	PCT			
	B04	WO 01/79299 A1	10/25/2001	PCT			
	B05	WO 03/035835 A2	05/01/2003	PCT			
	B06	WO 03/066095 A2	08/14/2003	PCT			
	B07	EP 0 359 096 B1	11/05/1997	EPC			
	B08	EP 1 006 183 A1	06/07/2000	EPC			
C.C.	B09	EP 0 343 950 B1	10/18/2000	EPC			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C.C.	C01	Abra et al., The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res. 2002 Feb-May;12(1-2):1-3
	C02	Bendas G, Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs. 2001;15(4):215-24.
C.C.	C03	Billadeau et al., ITAMs versus ITIMs: striking a balance during cell regulation, J Clin Invest. 2002 Jan;109(2):161-8

C.C.	C04	Bolland and Ravetch., Inhibitory pathways triggered by ITIM-containing receptors. <i>Adv Immunol.</i> 1999;72:149-177
	C05	Bolland et al., Genetic modifiers of systemic lupus erythematosus in FcγRIIB(-/-) mice. <i>J Exp Med.</i> 2002 May 6;195(9):1167-74
	C06	Boruchov et al., Expression and modulation of the inhibitory Fcγ receptor, FcγRIIb (CD32b), on human dendritic cells (DCs). Laboratory of Cellular Immunobiology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY, NY 10021
	C07	Brauweiler et al., Partially distinct molecular mechanisms mediate inhibitory FcγRIIB signaling in resting and activated B cells. <i>J Immunol.</i> 2001;167:204-211
	C08	Brown EJ., In vitro assays of phagocytic function of human peripheral blood leukocytes: receptor modulation and signal transduction. <i>Methods Cell Biol.</i> 1994;45:147-164
	C09	Budde et al., Specificity of CD32 mAb for FcγRIIa, FcγRIIb1, and FcγRIIb2 expressed in transfected mouse B cells and BHK-21 cells. <i>Leukocyte Typing V: White cell differentiation antigens.</i> 1995;828-832 (Schlossman, Bousmell, Gilks, Harlan, Kishimoto, eds.)
	C10	Callanan et al., The IgG Fc Receptor, FcγRIIB is a target for deregulation by chromosomal translocation in malignant lymphoma. <i>PNAS.</i> 2000 Jan;97(1):309-314.
	C11	Cameron et al., Differentiation of the human monocyte cell line, U937, with dibutyl cyclicAMP induces the expression of the inhibitory Fc receptor, FcγRIIb. <i>Immunol Lett.</i> 2002 Oct 1;83(3):171-9
	C12	Camilleri-Broët et al., FcγRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. <i>Br J Haematol.</i> 2004;124(1):55-62
	C13	Cassard et al., Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells. <i>The J Clin Invest.</i> 2002 November;110(10):1549-1557
	C14	Chappel et al., Identification of the Fcγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. <i>Proc. Natl. Acad. Sci. USA.</i> 1991 October;88(20):9036-9040
	C15	Clynes et al., Inhibitory Fc receptors modulate <i>in vivo</i> cytotoxicity against tumor targets. <i>Nat Med</i> 2000;6(4):443-6
	C16	Damle et al., B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. <i>Blood</i> 2002 June 1;99(11):4087-4093
	C17	Davies et al., Expression of GαTII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII. <i>Biotechnol Bioeng.</i> 2001 Aug 20;74(4):288-94
	C18	Daëron et al., The Same Tyrosine Based Inhibition Motif, in the Intracytoplasmic Domain of FcγRIIB, regulates negatively BCR, TCR- and FcR dependent cell activation. <i>Immunology.</i> 1995 Nov;3: 635-646
	C19	Ding et al., Inhibition of the function of the FcγRIIB by a monoclonal antibody to thymic shared antigen-1, a Ly-6 family antigen. <i>Immunology.</i> 2001 Sep;104(1):28-36
	C20	Eppstein et al., Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor. <i>Proc Natl Acad Sci U S A.</i> 1985 Jun;82(11):3688-92
	C21	Fanger et al., Production and use of anti-FcR bispecific antibodies. <i>Immunomethods.</i> 1994 Feb;4(1):72-81
	C22	Farag, et al., FcγRIIIa and FcγRIIIa polymorphisms do not predict response to Rituximab in B-cell chronic lymphocytic leukemia. <i>Blood.</i> 2003 Oct 16 (15 pp.)
	C23	Fidler, I. J., Macrophages and metastasis--a biological approach to cancer therapy. <i>Cancer Res.</i> 1985 Oct;45(10):4714-26.
	C24	Gerber et al., Stimulatory and inhibitory signals originating from the macrophage Fcγ receptors. <i>Microbes Infect.</i> 2001 Feb;3(2):131-9
	C25	Holmes et al., Alleles of the Ly-17 alloantigen define polymorphisms of the murine IgG Fc receptor. <i>Proc Natl Acad Sci USA.</i> 1985 Nov;82(22):7706-10
	C26	Hwang et al., Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study. <i>Proc Natl Acad Sci U S A.</i> 1980 Jul;77(7):4030-4
	C27	Isaacs et al., Therapy with monoclonal antibodies. II. The contribution of Fcγ receptor binding and the influence of C _H 1 and C _H 3 domains on <i>in vivo</i> effector function. <i>The Journal of Immunology.</i> 1998;161:3862-3869
	C28	Jefferis et al., Recognition sites on human IgG for Fcγ receptors: the role of glycosylation. <i>Immunol Lett.</i> 1995 Jan;44(2-3):111-7
	C29	Kagari et al., Essential Role of Fcγ Receptors in anti-type II collagen antibody induced arthritis. <i>J. Immunol.</i> Apr. 2003;170:4318-24
	C30	Lifely et al., Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. <i>Glycobiology.</i> 1995 Dec;5(8):813-22
	C31	Lin et al., Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. <i>J Exp Med.</i> 2001;193(6):727-739.
	C32	Lin et al., The macrophage growth factor CSF-1 in mammary gland development and tumor progression. <i>J Mammary Gland Biol Neoplasia.</i> 2002;7(2):147-62
	C33	Lyden et al., The Fc receptor for IgG expressed in the villus endothelium of human placenta is FcγRIIb2. <i>J Immunol.</i> 2001 Mar 15;166(6):3882-9
	C34	Malbec et al., Fcα receptor I-associated <i>lyn</i> -dependent phosphorylation of Fcγ receptor IIB during negative regulation of mast cell activation. <i>J Immunol.</i> 1998 Feb 15;160(4):1647-58
C.C.	C35	Maruyama K, <i>In vivo</i> targeting by liposomes. <i>Biol Pharm Bull.</i> 2000 Jul;23(7):791-9

C.C.	C36	Metcalfe, Mast Cells. <i>Physiol Rev.</i> 1997 Oct;77(4):1033-79
	C37	Micklem et al., Different isoforms of human FcRII distinguished by CDw32 antibodies. <i>J Immunol.</i> 1990 March;144:2295-2303
	C38	Nakamura et al., Fcγ receptor IIB-deficient mice develop Goodpasture's Syndrome upon immunization with Type IV collagen: a novel murine model for Autoimmune Glomerular Basement Membrane Disease. <i>J. Exp. Med.</i> 2000 March 6;191(5):899-905
	C39	Norris et al., A naturally occurring mutation in FcγRIIA: A Q to K ¹²⁷ change confers unique IgG binding properties to the R ¹³¹ allelic form of the receptor. <i>Blood.</i> 1998 January 15;91(2):656-662
	C40	Ott et al., Downstream of Kinase, p62 ^{cas} , is a mediator of FcγRIIB inhibition of FcεRI signaling. <i>J. of Immunol.</i> 2002;168:4430-9
	C41	Park et al., Immunoliposomes for cancer treatment. <i>Adv Pharmacol.</i> 1997;40:399-435
	C42	Park YS, Tumor-directed targeting of liposomes. <i>Biosci Rep.</i> 2002 Apr;22(2):267-81
	C43	Presta LG, Engineering antibodies for therapy. <i>Curr Pharm Biotechnol.</i> 2002 Sep;3(3):237-56
	C44	Pricop et al., Differential modulation of stimulatory and inhibitory Fcγ receptors on human monocytes by Th1 and Th2 cytokines. <i>J Immunol.</i> 2001 Jan 1;166(1):531-7
	C45	Pulford et al., A new monoclonal antibody (KB61) recognizing a novel antigen which is selectively expressed on a subpopulation of human B lymphocytes. <i>Immunology.</i> 1986 Jan;57(1):71-6
	C46	Qin et al., Fcγ receptor IIB on follicular dendritic cells regulates the B cell recall response. <i>J Immunol.</i> 2000;164:6268-6275
	C47	Ravetch and Bolland, IgG Fc receptors. <i>Annu Rev Immunol.</i> 2001;19:275-290
	C48	Ravetch et al., Fc Receptors. <i>Annu Rev Immunol.</i> 1991;9:457-92
	C49	Ravetch et al., Fc receptors: rubor redux. <i>Cell.</i> 1994 Aug 26;78(4):553-60
	C50	Ravetch et al., Immune inhibitory receptors. <i>Science.</i> 2000 Oct 6;290(5489):84-9.
	C51	Reall et al., IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. <i>Cancer Res.</i> 2001;61(14): 5517-22
	C52	Routledge et al., The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. <i>Transplantation.</i> 1995 Oct 27;60(8):847-53
	C53	Samuelsson et al., Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. <i>Science.</i> 2001 January 19; 291:484-486
	C54	Sarkar et al., Negative signaling via FcγRIIB1 in B cells blocks phospholipase Cγ2 tyrosine phosphorylation but not Syk or Lyn activation. <i>J Biol Chem.</i> 1996 Aug 16;271(33):20182-6
	C55	Scholl et al., Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis? <i>Mol Carcinog.</i> 7(4):207-11
	C56	Shields et al., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. <i>J Biol Chem.</i> 2002 Jul 26;277(30):26733-40
	C57	Sondermann et al., The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. <i>Nature.</i> 2000 Jul 20;406(6793):267-273
	C58	Tam et al., A bispecific antibody against human IgE and human FcγRII that inhibits antigen-induced histamine release by human mast cells and basophils. <i>Allergy</i> 2004;59:772-780
	C59	Tao and Morrison, Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. <i>J Immunol.</i> 1989 Oct 15;143(8):2595-601
	C60	Todorovska et al., Design and application of diabodies, triabodies and tetrabodies for cancer targeting. <i>J Immunol Methods.</i> 2001 Feb 1;248(1-2):47-66
	C61	Tridandapani et al., Regulated Expression and Inhibitory Function of FcγRIIb in Human Monocytic Cells, <i>Journal of Biol. Chem.</i> 277(7):50582-9
	C62	Umafia et al., Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. <i>Nat Biotechnol.</i> 1999 Feb;17(2):176-80
	C63	Van Nguyen et al., Colony stimulating factor-1 is required to recruit macrophages into the mammary gland to facilitate mammary ductal outgrowth. <i>Dev Biol.</i> 2002;247(1):11-25
	C64	Van Sorge et al., FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. <i>Tissue Antigens.</i> 2003;61:189-202
	C65	Vingerhoeds et al., Immunoliposomes in vivo. <i>Immunomethods.</i> 1994 Jun;4(3):259-72
	C66	Wallick et al., Glycosylation of a VH residue of a monoclonal antibody against d (1→6) dextran increases its affinity for antigen. <i>J Exp Med.</i> 1988 Sep 1;168(3):1099-109
	C67	Warmerdam et al., Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). <i>J Exp Med.</i> 1990 Jul 1;172(1):19-25
	C68	Weinrich et al., Epitope mapping of new monoclonal antibodies recognizing distinct human FcRII (CD32) isoforms. <i>Hybridoma</i> 1996 Nov 2; 15:109-116
	C69	Wright and Morrison, Effect of glycosylation on antibody function: implications for genetic engineering. <i>Trends Biotechnol.</i> 1997 Jan;15(1):26-32
C.C.	C70	Xu et al., FcγRs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody Based Therapeutics. <i>J Immunol.</i> 2003;171:562-68

C.C.	C71	Xu et al., Residue at position 331 in the IgG1 and IgG4 C _H 2 domains contributes to their differential ability to bind and activate complement. The Journal of Biological Chemistry, 1994 Feb 4;269(5):3469-3474
EXAMINER		DATE CONSIDERED 3/23/06
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		



Notice of References Cited

Application/Control No.
10/524,134

Applicant(s)/Patent Under
Reexamination
KOENIG ET AL.

Examiner
Chun Crowder

Art Unit
1644

Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
(*)	A	US-6,737,056	05-2004	Presta, Leonard	424/133.1
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ott et al. J. Allergy Clin. Immunol. 2001. 108:S95-S98).
	V	Reff et al. Critical Review i Oncology/Hematology. 2000. 40:25-35.
	W	
	X	

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.